Q4 2025 Insulet Corp Earnings Call Transcript
Key Points
- Insulet Corp (PODD) achieved its 10th consecutive year of 20% or greater constant currency revenue growth, showcasing the strength of its business model.
- The company reported a strong finish to 2025 with total revenues of $784 million in Q4, advancing 29% constant currency, and surpassing $2.7 billion in revenue for the full year.
- Insulet Corp (PODD) experienced record new customer starts in both the US and international markets, with significant growth in type 2 diabetes users.
- The company has expanded its prescriber base to over 30,000 healthcare professionals in the US, up approximately 28% year-over-year.
- Insulet Corp (PODD) plans to launch a fully closed-loop system in 2028, which is expected to further expand its market reach and serve the broader primary care population.
- Despite strong growth, Insulet Corp (PODD) faces challenges with new competition entering the market, which could impact its market share.
- The company anticipates a deceleration in growth rates for 2026 due to anniversarying the first full year of the US launch of Omnipod for type 2 and annualizing several international launches.
- Insulet Corp (PODD) reported an increase in net interest expense due to debt refinancing, impacting its financials.
- The company is investing heavily in R&D, which, while necessary for future growth, could pressure margins in the short term.
- There is a need to improve clinical acumen among healthcare providers regarding Insulet Corp (PODD)'s strong clinical performance, which is currently underappreciated.
Good morning and welcome to the Insulet Corporation fourth quarter and full year 2025 earnings call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Clare Trachtman, Vice President, Investor Relations.
Good morning and welcome to our fourth quarter in full year 2025 earnings call. Joining me today are Ashley Mcevoy, President and Chief Executive Officer, Flavia Pease, Chief Financial Officer, and Eric Benjamin, Chief Operating Officer.
On the call this morning, we will be discussing Insulet's fourth quarter and full year results along with our financial outlooks for the first quarter and full year 2026. With that, let me start our prepared remarks by reminding everyone that certain statements, including comments regarding our financial outlook for the first quarter in full year 2026.
The anticipated impact of our strategic actions, the potential impact of various regulatory and operational matters,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
